AIM: To observe the comparison of vitrectomy combined drug therapy(Ranibizumab injection)and single vitrectomy for proliferatived diabetic retinopathy(PDR)and the influence of the curative effect and prognosis of patients.

METHODS: In this study, 112 cases(125 eyes)with PDR were selected and randomly divided into experimental group and control group(n=56). Fifty-six cases(61 eyes)in experimental group were injected by drug therapy of 0.5mg ranibizumab and received vitrectomy; In control group, 56 cases(64 eyes)were received single vitrectomy. The intraoperative and postoperative differences of clinical indicators were analyzed in two groups.

RESULTS: The average operation time, intraoperative electric coagulation hemostasis rate and iatrogenic hiatal incidence of the experimental group were lower than that of the control group:(95.00±13.00)min vs(133.00±14.5)min, 11% vs 34%, 5% vs 20%, respectively(P<0.05). The anterior chamber and vitreous body cavity hemorrhage rate within postoperative 1mo in the experimental group were lower than that of the control group: 7% vs 23%, 5% vs 12%, respectively(P<0.05). The postoperative visual acuity of experimental group was better than that of the control group: 0.375±0.210 vs 0.261±0.170, respectively(P<0.05).

CONCLUSION: Patients with PDR injected with ranibizumab in vitreous cavity before vitrectomy can effectively reduce the operation time, less intraoperative blood loss, the incidence of iatrogenic hiatus, and intraoperative and postoperative complications. The postoperative visual acuity was better than before.